This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 Sep 29;16(10):669.

doi: 10.1038/nrd.2017.196.

FDA approves first CAR T therapy

PMID: 28959944
DOI: 10.1038/nrd.2017.196

FDA approves first CAR T therapy

Asher Mullard. Nat Rev Drug Discov. 2017.

. 2017 Sep 29;16(10):669.

doi: 10.1038/nrd.2017.196.

Author

PMID: 28959944
DOI: 10.1038/nrd.2017.196

No abstract available

PubMed Disclaimer

Similar articles

FDA Approves Second CAR T-cell Therapy.
[No authors listed] [No authors listed] Cancer Discov. 2018 Jan;8(1):5-6. doi: 10.1158/2159-8290.CD-NB2017-155. Epub 2017 Nov 7. Cancer Discov. 2018. PMID: 29113977
FDA approves first BCMA-targeted CAR-T cell therapy.
Mullard A. Mullard A. Nat Rev Drug Discov. 2021 May;20(5):332. doi: 10.1038/d41573-021-00063-1. Nat Rev Drug Discov. 2021. PMID: 33790473 No abstract available.
FDA approves fourth CAR-T cell therapy.
Mullard A. Mullard A. Nat Rev Drug Discov. 2021 Mar;20(3):166. doi: 10.1038/d41573-021-00031-9. Nat Rev Drug Discov. 2021. PMID: 33574586 No abstract available.
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC, Duncan BB, Lee DW. Pehlivan KC, et al. Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x. Curr Hematol Malig Rep. 2018. PMID: 30120708 Review.
CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. Mollanoori H, et al. Hum Immunol. 2018 Dec;79(12):876-882. doi: 10.1016/j.humimm.2018.09.007. Epub 2018 Sep 24. Hum Immunol. 2018. PMID: 30261221 Review.

See all similar articles

Cited by

Application of novel CAR technologies to improve treatment of autoimmune disease.
Cheever A, Kang CC, O'Neill KL, Weber KS. Cheever A, et al. Front Immunol. 2024 Oct 9;15:1465191. doi: 10.3389/fimmu.2024.1465191. eCollection 2024. Front Immunol. 2024. PMID: 39445021 Free PMC article. Review.
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.
Nasiri F, Kazemi M, Mirarefin SMJ, Mahboubi Kancha M, Ahmadi Najafabadi M, Salem F, Dashti Shokoohi S, Evazi Bakhshi S, Safarzadeh Kozani P, Safarzadeh Kozani P. Nasiri F, et al. Front Immunol. 2022 Nov 22;13:1018786. doi: 10.3389/fimmu.2022.1018786. eCollection 2022. Front Immunol. 2022. PMID: 36483567 Free PMC article. Review.
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. Choi BD, et al. J Immunother Cancer. 2019 Nov 14;7(1):304. doi: 10.1186/s40425-019-0806-7. J Immunother Cancer. 2019. PMID: 31727131 Free PMC article.
Humanized Chimeric Antigen Receptor (CAR) T cells.
Kozani PS, Kozani PS, O'Connor RS. Kozani PS, et al. J Cancer Immunol (Wilmington). 2021;3(4):183-187. J Cancer Immunol (Wilmington). 2021. PMID: 35128536 Free PMC article. No abstract available.
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung SI. Pan RY, et al. J Immunol Res. 2018 Dec 19;2018:4325874. doi: 10.1155/2018/4325874. eCollection 2018. J Immunol Res. 2018. PMID: 30662919 Free PMC article. Review.

See all "Cited by" articles

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations